- Hemoglobin-Based Oxygen Carriers
- Perflurocarbon-Based Products
- Recombinant Factors
- Synthetic Platelets
- Plasma Expanders
Artificial blood or synthetic blood and blood products are the alternatives to the blood transfusion to replace the blood. It fulfills and replicates the normal functions of the body. Artificial blood is infused in the traumatic injuries and other disease conditions for the transportation of carbon di oxide and oxygen across the body. Moreover, scientists are focusing on the development of artificial blood due to inadequate number of blood donors leads to shortage of blood. However, there are adverse effects associated with the artificial blood such as hemoglobin based blood substitute might increase the occurrence of heart attacks.
Fastest Growing Market
Drivers: Increase in the prevalence of anemia and other blood disorders Rise in R&D for the innovation of newer products Increase in healthcare expenditure and well developed healthcare infrastructure Restraints: Lower shelf-life and instability of artificial blood Adverse effects associated with artificial blood substitutes Stringent regulatory guidelines for product approval
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.